Metabolomics reveals that dietary xenoestrogens alter cellular metabolism induced by palbociclib/letrozole combination cancer therapy
B. Warth, P. Raffeiner, A. Granados, T. Huan, M. Fang, E. M. Forsberg, H. P. Benton, L. Goetz, C. Johnson, G. Siuzdak
Abstract
HighlightsO_LISynergism of combined palbociclib/letrozole chemotherapy was examined by global metabolomics\nC_LIO_LICombination therapy led to more pronounced effects on the MCF-7 metabolome than single agents\nC_LIO_LIDietary phyto- and mycoestrogens significantly affected the metabolic and anti-oncogenic response of the drugs\nC_LIO_LIImplications of these bio-active chemicals on therapeutic success in breast cancer patients appear plausible\nC_LI\n\nIn BriefWarth et al. used innovative global metabolomics and pathway prediction technology to describe the metabolic effects of the combined palbociclib/letrozole breast cancer therapy. Moreover, the role of dietary xenoestrogens on this treatment was examined by metabolite data, proliferation experiments, and functional assays.\n\nSummaryRecently, the palbociclib/letrozole combination therapy was granted accelerated FDA approval for the treatment of estrogen receptor (ER) positive breast cancer. Since the underlying metabolic effects of these drugs are yet unknown, we investigated their synergism at the metabolome level in MCF-7 cells. As xenoestrogens interact with the ER, we additionally aimed at deciphering the impact of the phytoestrogen genistein, and the estrogenic mycotoxin zearalenone on this treatment. A global metabolomics approach was applied to unravel metabolite and pathway modifications. The results clearly showed that the combined effects of palbociclib and letrozole on cellular metabolism were far more pronounced than that of each agent alone and potently influenced by xenoestrogens. This behavior was confirmed in proliferation experiments and functional assays. Specifically, amino acids and central carbon metabolites were attenuated while higher abundances were observed for fatty acids and most nucleic acid related metabolites. Interestingly, exposure to model xenoestrogens appeared to partially counteract these effects.
02 /Specification & Classification
Click any tag to browse matching papers- Organism
- Assay
- Research Focus
- Approach
Reproducibility ledger
Nobody has reported trying to reproduce this paper yet. Did you replicate an experiment or run the code? Your report saves the next lab a week.
Sign in to file a reproducibility report.
Related papers
- Palbociclib and fulvestrant act in synergy to modulate central carbon metabolism in breast cancer cells
B. Warth, A. Palermo, … C. Johnson·bioRxiv·Jun 16, 2018
- Metabolic reprogramming and synergistic cytotoxicity of genistein and chemotherapy in human breast cancer cells
Sandra Tobón‐Cornejo, Ariana Vargas‐Castillo, … Alejandro Schcolnik‐Cabrera·Life SciencesPeer-reviewed·Mar 14, 2025
- Conjugation of palbociclib with MHI-148 has an increased cytotoxic effect for breast cancer cells and an altered mechanism of action
- Deconstructing the contributions of heterogeneity to combination treatment of hormone sensitive breast cancer
S. Linn, J. Moore-Ott, … A. L. Jenner·bioRxiv·May 19, 2023
- WEE1 inhibition delays resistance to CDK4/6 inhibitor and antiestrogen treatment in estrogen receptor-positive breast cancer
Wei He, Diane M. Demas, … William T. Baumann·npj Systems Biology and ApplicationsPeer-reviewed·Nov 17, 2025
- Estrogen and Soy Isoflavonoids Decrease Sensitivity of Medulloblastoma and Central Nervous System Primitive Neuroectodermal Tumor Cells to Chemotherapeutic Cytotoxicity
S. M. Belcher, C. C. Burton, … K. E. Wray·BMC Pharmacology and ToxicologyPeer-reviewed·Sep 6, 2017